Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost
Our experience with gETI is similar to real-world reports using the originator product. Boosting ETI with CYP3A-inhibitors is a safe and effective strategy to increase access to ETI in settings where access to HEMT is restricted.
Authors
- Marco Zampoli (ORCID: https://orcid.org/0000-0002-6899-6137)
- Dickinson W. Richards
- Janine Verstraete (ORCID: https://orcid.org/0000-0002-1148-4747)
- Carla Els
- Greg Calligaro (ORCID: https://orcid.org/0000-0001-7324-0775)
- Andrew Hill (ORCID: https://orcid.org/0000-0002-6494-7645)
- Marlize Frauendorf
- Hanri Truter
- Marina Coetzee
- Paul Gebers
- Cathy Baird
- Tony Biebuyck
Institutions
- University of Liverpool (GB)
- Milpark Hospital (ZA)
- Johannesburg Hospital (ZA)
- Groote Schuur Hospital (ZA)
- Panorama Research (United States) (US)
- Netcare Unitas Hospital (ZA)
- Red Cross War Memorial Children's Hospital (ZA)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.jcf.2025.02.002
- Citations
- 4
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 6.07